Member Info for uinsionn

not many sellers bur buyers picking up what they are offering, looks like they are just playing around to find volumes, dropped it enough got bought right back up

that was yesterday my friend, seen a paper saying p140 needs more investigation with regard to covid 19, might tie in with trump taking a drug used for LUPUS

Its only confirmed what we already were pretty sure off, as the volume last week was meet with a large seller, looks like they have taken some off, lets see what the next news item brings, they created an orderly market so happy days, next news could push us over the 20p point and higher on, its all about the build up now

Its defo no pump and dump, no pumpers on it, something thats undervalued at price isnt a pump, people will be paying multiples of this on newsflow, its about story at price, at the moment there is a story to unfold and its not priced in, value buy here and rewards are much higher.

Hate being called a twitter ramper its not very nice, more a promoter of undervalued stocks, anyway all the info is in the presentation so no ramping required, this has potential to move massively over the next 12 months, on first production they are looking at a MCAP int he region of 12m, full production is times this so a Mcap of 40m isnt out of the qustion which a 10 bagger in my book, got to look at his from a med to long form. But right here right now its a bargain.

someone god a big background buy going on, they are happy yo take more and trying to limit in range, next update on covid 19 could be a big one here

Antiviral Opportunity
ImmuPharma through its subsidiary Ureka Pharma has recently become a partner in a consortium dedicated to the development of novel peptides intended to block the fusion of COVID-19 and other viruses to the target cell, an approach similar to Fuzeon (enfuvirtide) by Roche.

Drugs that target viral entry into the host cell have been proven effective against a wide range of viral diseases. The aim is to apply the results of fundamental research to the development of novel inhibitors of SARS-CoV-2 entry into target cells using the Urelix™ patented technology of Ureka Pharma together with contributions from the other members of the consortium. The strategy is based on inhibiting viral entry using peptides specific for the viral fusion protein.

I have concentrated my activity on systemic lupus erythematosus (SLE), which represents a prototype of autoimmune rheumatic disease. SLE is characterized by inflammation and damage to various tissues, complement deficiencies, modification of cytokine secretion and production of autoantibodies. At least 100 different antigens, often nuclear, targeted by specific antibodies have been characterized in SLE. The cause of the illness is poorly understood, multifactorial in essence, depending on risk factors that are genetic, hormonal (with a female prevalence) and environmental. Over the recent years, I have focused my research activity on the pathways involved in autoreactive lymphocytes activation and on molecular events leading to cell death/living phenomena (apoptosis, autophagy) that are central in lupus. Combining my fundamental knowledge of lupus with my long lasting experience in peptide chemistry has enabled me, with my team, to develop very novel strategies to modulate the aberrant immune response and restore normal immune functions using synthetic peptides.

Was just responding to the the other chart guy who was down talking the share price, we broke and held 16p, it was building towards 16p pre news item and chart indication was to 20p pre news, now we enter a news rich period all I am saying is the price point is higher not saying how high as the market decides that not someone on a BB. I am bullish here, all the links are here.

Will key support is 16p, might drop to 15.5 to find volume, if that area holds, a new trading range is made which will be 16-20p, the 20p area is key, if that can get broken then there is a bigger move to come. At the moment judging on the buys and demand around this area I would say 16p area will hold, I know there are some buy orders set around this area, also if you check the large trades they were in the higher region 17-19p which means shares will limit in this area. Tim stated more news to come on several fronts only takes one good news item here to turn it bullish, yes the end game is a year away, but position will build well before that, like I say some big trades over the last couple of weeks, they were not 2k ramp brigade, I expect on our big volume day major holder took advantage to offload some, which is a good thing. 4/5 possible updates to come in coming weeks, which will be value adding or value creation if distribution deals. Everything on the markets is based not on now but the future, I believe the future is looking good from this price

15.5k on the bell buy at 17.14, over the ask price, well according to some of the guys on here he is mad, not that many made ones chucking 15k around in the current market on on main market companies, he wanted in before close of play, other wise he would have waited until it dropped on monday morning as these guys are telling you. good consolidation today, very same guy deramping today was saying yesterday its a spike and will be 30% down tomorrow, well its not 30% from close yesterday, its down compared to where some entered but thats just an entry, you dont loose or gain until you sell FELLA. consolidation, chart was saying 20p before news anyway, as a trader you would have know that, it rounds up here and moves up to meet the 20p, then we get a moment of decision does it go higher or go back down, newsflow drives any share price and hopefully we got plenty to come.

Thats all fine and dandy fella , obvs a trader in stocks that not a problem there is a trade in every stock, have had about 40 trades this week, also been buying here over the last few weeks have had comms with the company as thats the kind of investor/trader i am. Been at this game a long time, survived the markets as they say, i think the company is undervalued at price, you have to look to the future and whats the pipeline otherwise you make nothing as an investor, you are not buying for today you are buying for tomorrow or the future, is it cheap at price with a story to unfold and I say yes it is, Big money trades in this the last few weeks, guys nudging in as we call it. volumes yesterday of 1500 trades and big money coming in higher than todays price we are not talking spunk money twitter trades or ramp the tiny mcap trades solid big numbers. This isnt a 2/3m mcap company its a 30m mcap company with roughly 2m cash in the bank and a 25m funded drug, so that 27m available money, now on top of that we are part of the french government consortium on covid 19, i would imagine grants and funding will be provided for that. We have a phase 3 drug LUPUZOR which could become a market leader in its area with a predicted market of around $3b worldwide, compared to our rival if all goes well we will have more benefits for the user, less side effects and cheaper as a long term solution, so working on the LUPUZOR can also be applied to other illness not even factored in. Avion have done their DD they have put their cash up and this time the company is confident that its going there way, predicting the future is hard and seeing more gains to be had to be had here as in investor are hard too, but if over the next 12 months this product get commercialisation then this could bee a 200m mcap plus with other products in development and other subs who knows but vision is required rather than being a basher, if you were the socalled amazing trader that you are you would be ramping to sell, deramping means you want to be again. No one in the marekts on LSE is just giving out advice to be nice, no nice in the markets

"As the Covid-19 pandemic has unfolded, ImmuPharma has been evaluating how it can best contribute its expertise and resources to help in the global response. Using our longstanding knowledge of peptide based technology, provides us with a number of opportunities, to help bring together a therapy that could be effective against the inflammation that causes the serious complications of Covid-19. We look forward to providing further updates when appropriate".

So sorry lump we didn't know you wanted more at a cheap price, if we did know we wouldn't have said anything, we were just doing the maths over this one and realised at first stage production its probably got a mcap in the region of 30-40m and on ramp up to full production you are probably looking at 130-150m Mcap. Will try not to mention it again as for heavens sake we dont want to price to rise and we all make loads of profit from our very cheap entry which we have had loads of time to gather down here. Sorry again hope someone sells so you can get some more before this 10 bags. 10 BAGGER ALERT

Strong support in this area, thought they would have worked it lower but they cant, trying to hold it from breaking out here by offering very little and will take large amounts, i expect there is more news to come from Tim and they are playing the smart game here, EVEN WEIRDER the volumes yesterday were not backed up by twitter or telegram groups ramping this, so the buyers are not spunk your cash todays ramp crew, someone has been gathering since last thursday as we have seen increased volumes, think there is something bigger to come IMO

Antiviral Opportunity
ImmuPharma through its subsidiary Ureka Pharma has recently become a partner in a consortium dedicated to the development of novel peptides intended to block the fusion of COVID-19 and other viruses to the target cell, an approach similar to Fuzeon (enfuvirtide) by Roche.

Drugs that target viral entry into the host cell have been proven effective against a wide range of viral diseases. The aim is to apply the results of fundamental research to the development of novel inhibitors of SARS-CoV-2 entry into target cells using the Urelix™ patented technology of Ureka Pharma together with contributions from the other members of the consortium. The strategy is based on inhibiting viral entry using peptides specific for the viral fusion protein.

Autoimmunity
Lupuzor™, is also known by its chemical name ‘Forigerimod’ or P140. ImmuPharma in conjunction with the CNRS, its collaboration partner, is exploring other opportunities around Lupuzor™’s mechanism of action and its applicability through its P140 platform to expand into other autoimmune conditions outside of Lupus. Chronic Inflammatory Demyelinating Polyneuropathy (“CIDP”) where compelling pre-clinical data has been generated, will now move into a proof of concept study. CIDP could potentially be granted ‘Orphan Drug Designation’ which would provide a fast approval process

mmuPharma’s subsidiary ‘Ureka Pharma’ has initiated the development of a novel and innovative peptide technology platform through the collaboration with CNRS, gaining access to pioneering research centred on novel peptide drugs at the University of Bordeaux and the Institut Européen de Chimie et Biologie (IECB). Jointly, ImmuPharma and CNRS have filed a new co-owned patent controlling this breakthrough peptide technology. The first therapeutic area being targeted is diabetes with glucagon-lik peptide -1 agonists, a class of drugs for the potential treatment of diabetes, as well as initiating the development of novel peptides as glucagon antagonists – one of the novel approaches to treat Type I and Type II diabetes.

ImmuPharma’s portfolio consists of four novel peptide therapy areas which are: Autoimmunity, Metabolism, Cancer and Anti-Infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of Lupus, a life threatening auto immune-disease. Lupuzor™ received ‘Gold Standard’ approval from the US FDA for its Phase III trial with a Special Protocol Assessment and “Fast Track” designation.

Preclinical analysis suggest that there are also opportunities around the therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
muPharma is now embarking on a further Phase III trial of Lupuzor™ with Avion Pharmaceuticals, in an exclusive licence and development agreement in the US, where Avion Pharmaceuticals will fund the new Phase III trial.

ImmuPharma is led by a commercially focused Board and management team with extensive industry experience.

Can defo see this returning to over £1 in the coming months its a sit back and wait share, at some point we are going to recieve a pay day here, as tim said its a new chapter in the company, there is no such thing as a failed drug it was just a failed trial, AVION will have done major research here before stumping up 25m for us to move forward, industry backing

I have taken a large holding in here over the last few weeks, didnt sell any yesterday, this for me right now is a hold as we will be multiples of this price over the coming months as LUPUZOR advances, its fully funded with 25m from AVION, huge upside from here, the covid play is good but at the end of the day this company has alot to offer on other levels too.